Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed Phase 1 trial of its novel antifungal, VL-2397, at the American Society of Microbiology (ASM) Microbe …